the logo of the Biotrial laboratory on its building in Rennes where a clinical trial of an oral medication left one person brain-dead and five hospitalised. The study was a phase one clinical trial, in which healthy volunteers take the medication to 'evaluate the safety of its use, tolerance and pharmacological profile of the molecule', French Health Minister Marisol Touraine said in a statement.
Getty Images
the logo of the Biotrial laboratory on its building in Rennes where a clinical trial of an oral medication left one person brain-dead and five hospitalised. The study was a phase one clinical trial, in which healthy volunteers take the medication to 'evaluate the safety of its use, tolerance and pharmacological profile of the molecule', French Health Minister Marisol Touraine said in a statement.
Now playing
02:13
Drug trial leaves a man brain dead
Now playing
01:10
Trouble sleeping? This may be why
Woman pointing to area on mammogram x-ray, close-up
Getty Images/File
Woman pointing to area on mammogram x-ray, close-up
Now playing
01:19
Breast cancer: Know the facts
Laboratory Fertilization Of Eggs In IVF Treatment  Stock Photo:Image ID: 155727377
Shutterstock
Laboratory Fertilization Of Eggs In IVF Treatment Stock Photo:Image ID: 155727377
Now playing
03:06
Explain it to me: Fertility
Ways to treat heartburn_00000026.jpg
Ways to treat heartburn_00000026.jpg
Now playing
02:40
Ways to treat heartburn
CNN
Now playing
02:13
Why losing weight might protect you from Covid-19
this is your brain on pain health orig_00001025.jpg
CNN
this is your brain on pain health orig_00001025.jpg
Now playing
01:39
This is your brain on pain
Now playing
01:42
Here's why you can't stop eating pizza, ice cream and chocolate chip cookies
shutterstock
Now playing
01:49
These foods aren't as healthy as you think
Americans are still too fat according to a new study from JAMA. Two in three of Americans are registering as overweight or obese.
Shutterstock
Americans are still too fat according to a new study from JAMA. Two in three of Americans are registering as overweight or obese.
Now playing
01:15
What is obesity?
CNN
Now playing
01:17
Why your BMI matters
LONDON - MAY 16:  In this photo illustration a cigarette is seen burning on May 16, 2007 in London. Businesses and shops are gearing up for the introduction of the smoking ban on July 1 in England after similar bans have been introduced in Ireland, Scotland and Wales.  (Photo Illustration by Bruno Vincent/Getty Images)
Bruno Vincent/Getty Images Europe/Getty Images
LONDON - MAY 16: In this photo illustration a cigarette is seen burning on May 16, 2007 in London. Businesses and shops are gearing up for the introduction of the smoking ban on July 1 in England after similar bans have been introduced in Ireland, Scotland and Wales. (Photo Illustration by Bruno Vincent/Getty Images)
Now playing
01:07
What tobacco does to your health (2017)
Photo Illustration/Thinkstock
Now playing
01:12
World blood pressure rises (2016)
A surgeon sitting in front of screens of a Focal One device performs a robot-assisted prostate tumorectomy using ultrasound imaging on April 10, 2014 at the Edouard Herriot hospital in Lyon, center France. Focal One is the first robotic HIFU (high intensity focused ultrasound) device dedicated to the focal approach for prostate cancer therapy. According to EDAP TMS SA, a leader in therapeutic ultrasound, it combines the three essential components to efficiently perform a focal treatment: state-of-the-art imaging to localized tumors with the use of magnetic resonance imaging (MRI) combined with real-time ultrasound, utmost precision of robotic HIFU treatment focused only on identified targeted cancer areas, and immediate feedback on treatment efficacy utilizing Contrast-Enhanced Ultrasound Imaging. AFP PHOTO / JEFF PACHOUD        (Photo credit should read JEFF PACHOUD/AFP/Getty Images)
JEFF PACHOUD/AFP/AFP/Getty Images
A surgeon sitting in front of screens of a Focal One device performs a robot-assisted prostate tumorectomy using ultrasound imaging on April 10, 2014 at the Edouard Herriot hospital in Lyon, center France. Focal One is the first robotic HIFU (high intensity focused ultrasound) device dedicated to the focal approach for prostate cancer therapy. According to EDAP TMS SA, a leader in therapeutic ultrasound, it combines the three essential components to efficiently perform a focal treatment: state-of-the-art imaging to localized tumors with the use of magnetic resonance imaging (MRI) combined with real-time ultrasound, utmost precision of robotic HIFU treatment focused only on identified targeted cancer areas, and immediate feedback on treatment efficacy utilizing Contrast-Enhanced Ultrasound Imaging. AFP PHOTO / JEFF PACHOUD (Photo credit should read JEFF PACHOUD/AFP/Getty Images)
Now playing
01:21
What is prostate cancer?
Argosy
Now playing
00:53
What is Parkinson's disease?
Now playing
01:38
How Alzheimer's destroys the brain

Story highlights

NEW: Bial says drug was already given to 108 people with no "serious adverse reaction"

The drug was being tested to help people with anxiety disorders and motor skills issues

The French Health Ministry is investigating what went wrong

(CNN) —  

A man has died in France after participating in a clinical drug trial, the University Hospital of Rennes said in a statement Sunday.

The French Health Ministry is investigating what it calls a “serious accident.”

Four of the patients may be permanently disabled with neurological damage, doctors in the northwestern city of Rennes said. One other person doesn’t have symptoms but remains under medical surveillance.

The company conducting the testing said on its website the trial was administered “in full compliance with the international regulations and Biotrial’s procedures were followed at every stage throughout the trial.”

Biotrial International said it was “in close and regular contact with the Health Authorities and Ministry in France.”

The first patients to get sick started to show symptoms January 10 and were hospitalized in Rennes. The testing has been stopped, Health Minister Marisol Touraine said in a news conference Friday, and health authorities have been reaching out to the rest of the volunteers to let them know about these adverse effects.

French Social Affairs and Health minister Marisol Touraine and Professor Gilles Edan hold a news conference Friday.
DAMIEN MEYER/AFP/AFP/Getty Images
French Social Affairs and Health minister Marisol Touraine and Professor Gilles Edan hold a news conference Friday.

The drug being tested is a painkiller meant to treat anxiety and motor disorders, and was designed to work on the body’s endogenous cannabinoid system, which deals with pain. Earlier reports said the drug was related to cannabis, but Touraine insisted that the drug – developed by the Portuguese science group Bial – does not contain cannabis or cannabis extracts.

A total of 128 volunteers took part in the drug test. The subjects were between the ages of 18 to 55 and were considered healthy. Ninety people were given different level dosages of the drug and the rest got the placebo.

Volunteers began taking the drug on January 7 in early testing known in the industry as Phase I, in which it’s determined if the drug is safe for human consumption. Scientists also measure the effectiveness of a drug at this phase and can watch to see how it reacts at different doses in the human body.

Earlier testing of the drug in question involved animals, the health minister said. While animals can react similarly to humans, their bodies can process substances differently. In order for any drug to get to market, it must go through several government-approved steps along the way that involve human subjects.

Such extreme adverse reactions to drugs in these early phases of drug trails are incredibly rare.

Bial pharmaceutical said in statement that throughout this trial, the new drug had already been administered to 108 patients “without any moderate or serious adverse reaction.”

The French health ministry said it immediately sent agents to the medical facility to determine if all the rules had been followed in the testing and if the facility where the patients were staying during the trial maintained sanitary conditions. The facility was inspected in 2014 and the ministry said it had favorable inspections.

Follow CNN Health on Facebook and Twitter

CNN’s Kellie Morgan contributed to this report.